Seer earnings release, May 13, 2026

Seer, Inc. (SEER) · Form 8-K, Item 2.02 · Filed · SEC filing

Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

REDWOOD CITY, Calif. – May 13, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026.

Recent Highlights

• Achieved revenue of $2.8 million in the first quarter of 2026

• Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer’s platform

• Secured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapore residents

• Strengthened the leadership team with the appointment of Anthony (Tony) Bazarko as Chief Commercial Officer, bringing deep expertise to drive strategy, partnerships, and market adoption.

• Successfully defended and reinforced Seer's IP position through a U.S. Patent and Trademark Office Final Written Decision

• Repurchased approximately 1.5 million Class A common shares under our share repurchase program authorization

• Ended the quarter with approximately $220 million of cash, cash equivalents, and investments

"Seer executed on several important drivers to advance the long-term trajectory of the business by generating traction on large-scale contracts with biobanks and supporting continued third-party validation of our platform," said Omid Farokhzad, Chair and Chief Executive Officer. "Seer sits at the forefront of deep, unbiased proteomics, a large and expanding market with profound scientific and commercial potential. We are building this market from the ground up, and the foundation we are laying is increasingly recognized by the world's leading scientists and institutions. We look forward to advancing our vision to empower the scientific community with unbiased proteomics solutions while creating value for all stakeholders."

First Quarter 2026 Financial Results

Revenue was $2.8 million for the first quarter of 2026, a 34% decrease from $4.2 million for the corresponding prior year period, primarily due to the continued depressed academic funding environment and competitive activity in the space we have pioneered. Product revenue for the first quarter of 2026 was $2.1 million, consisting of sales of Proteograph instruments and consumable kits. Service revenue was $596 thousand for the first quarter of 2026, including $56 thousand of related party revenue, and primarily consisting of revenue related to Seer Technology Access Center service projects. Other revenue was $87 thousand for the first quarter of 2026.

Gross profit was $982 thousand and gross margin was 35% for the first quarter of 2026.

Operating expenses were $18.2 million for the first quarter of 2026, including $2.1 million in stock-based compensation, a decrease of 20% compared to $22.8 million for the corresponding prior year period, including $4.5 million in stock-based compensation. The decrease in operating expenses was primarily driven by a decrease in employee compensation expenses, including stock-based compensation.

Net loss was $16.8 million for the first quarter of 2026, compared to $19.9 million for the corresponding prior year period.

Free cash flow, defined as net cash used in operating activities of approximately $15.4 million, less net purchases of property and equipment of approximately $270 thousand, for the quarter was approximately negative $15.7 million.

Cash, cash equivalents and investments were approximately $220 million as of March 31, 2026.

2026 Guidance

Seer continues to expect full year 2026 revenue to be in the range of $16 million to $18 million, representing growth of 3% at the midpoint over full year 2025.

Webcast Information

Seer will host a conference call to discuss the first quarter 2026 financial results on Wednesday, May 13, 2026, at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (in thousands, except share and per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Product2,1102,890
Revenue:Service5401,203
Revenue:Related party5652
Revenue:Other8760
Revenue:Total revenue2,7934,205
Cost of revenue:Product1,3951,374
Cost of revenue:Service170531
Cost of revenue:Related party670
Cost of revenue:Other240169
Cost of revenue:Total cost of revenue1,8112,144
Cost of revenue:Gross profit9822,061
Operating expenses:Research and development8,80611,350
Operating expenses:Selling, general and administrative9,43211,442
Operating expenses:Total operating expenses18,23822,792
Operating expenses:Loss from operations-17,256-20,731
Other income (expense):Interest income2,2253,217
Other income (expense):Loss on equity method investment-1,728-1,575
Other income (expense):Other expense-68-758
Other income (expense):Total other income429884
Other income (expense):Loss before provision for income taxes-16,827-19,847
Other income (expense):Provision for income taxes10101
Other income (expense):Net loss-16,837-19,948
Other comprehensive loss:Unrealized gain (loss) on available-for-sale securities-523169
Other comprehensive loss:Comprehensive loss-17,360-19,779
Other comprehensive loss:Net loss per share attributable to Class A and Class B common stockholders, basic and diluted-0.3-0.34
Other comprehensive loss:Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted55,995,93359,408,711

Balance Sheet

March 31, 2026 — (in thousands, except share and per share amounts)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents47,31847,285
Current assets:Short-term investments119,354138,612
Current assets:Accounts receivable, net3,2004,282
Current assets:Related party receivables56300
Current assets:Other receivables1,0001,370
Current assets:Inventory8,0797,795
Current assets:Prepaid expenses and other current assets2,5861,890
Current assets:Total current assets181,593201,534
Current assets:Long-term investments52,84854,686
Current assets:Operating lease right-of-use assets19,89020,488
Current assets:Property and equipment, net13,48514,754
Current assets:Restricted cash524524
Current assets:Other assets3,7924,097
Current assets:Total assets272,132296,083
Current liabilities:Accounts payable2,4975,611
Current liabilities:Accrued expenses4,7307,135
Current liabilities:Deferred revenue334341
Current liabilities:Operating lease liabilities, current2,6442,575
Current liabilities:Other current liabilities3829
Current liabilities:Total current liabilities10,24315,691
Current liabilities:Operating lease liabilities, net of current portion20,38421,077
Current liabilities:Other noncurrent liabilities268
Current liabilities:Total liabilities30,65336,776
Stockholders’ equity:Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 55,065,984 and 56,219,599 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively11
Stockholders’ equity:Additional paid-in capital724,351724,819
Stockholders’ equity:Accumulated other comprehensive gain (loss)-64459
Stockholders’ equity:Accumulated deficit-482,809-465,972
Stockholders’ equity:Total stockholders’ equity241,479259,307
Stockholders’ equity:Total liabilities and stockholders’ equity272,132296,083
Full release

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s plans and expectations regarding the adoption of Seer’s products. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:... (trSchmidt pr@seer.bio

Investor Contact:

Marissa Bych investor@seer.bio

SEER, INC.

Condensed Consolidated Statements of O perations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)

SEER, INC.

Condensed Consolidated

Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Seer earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.